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tions. Some of these adaptations are focused on avoiding 
the retention of specific micro- and macronutrients to 
toxic levels. Other approaches seek to retard kidney dam-
age and slow progression to end-stage renal disease 
(ESRD). Finally, the increased prevalence of malnutrition 
in advanced CKD stages provides another scenario for 
dietary modification. This review aims at offering a gen-
eral overview of current dietary recommendations in 
nondialyzed CKD patients before the start of dialysis.
 Nutritional Considerations for Halting CKD 
Progression 
 The evidence that lifestyle factors may be involved in 
the incidence and progression of CKD is mounting. Pro-
tein restrictive diets have been the subject of much re-
search and debate, and the inevitable link between salt 
intake and hypertension demands salt control in patients 
with reduced renal function. In addition, modern nutri-
tional epidemiology has identified other unhealthy di-
etary habits that may be associated with the development 
of CKD. When interpreting the following studies, it 
should be emphasized, however, that modifying dietary 
habits is challenging and implies a major change in life-
style. Indeed, it may be more difficult to implement and 
evaluate dietary than drug interventions.
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 Abstract 
 Dietary management of chronic kidney disease (CKD) fo-
cusses on limiting the intake of substances that might accu-
mulate to toxic levels (such as potassium, phosphorus or 
salt) and, although still a matter of debate for some, restrict-
ing dietary protein to retard kidney damage. Recent evi-
dence brings the opportunity to revisit the role of a healthy 
diet on disease progression and on some of the cardiometa-
bolic complications of moderate/advanced CKD, such as in-
flammation or oxidative stress control. This review provides 
a brief overview of dietary strategies that delay CKD progres-
sion and CKD complications, and discusses currently limited 
data addressing the development of malnutrition and pro-
tein-energy wasting before dialysis initiation. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 The kidney plays an essential role in nutrient homeo-
stasis and electrolyte and fluid control. Thus, the presence 
of reduced kidney function and development of chronic 
kidney disease (CKD) requires specific dietary adapta-
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 Low-Protein Diets 
 Animal studies from the 1960s showed that a high-
protein diet results in glomerular hyperfiltration and sub-
sequent kidney injury  [1] , and population-based cohorts 
seem to confirm these deleterious effects of high intake of 
nondairy animal protein on renal function  [2] . Thus, it is 
generally recommended that excessive protein intake be 
avoided by individuals with CKD, and moderate restric-
tion on dietary protein is advocated. The latest KDIGO 
guidelines suggest the consumption of a high-quality pro-
tein diet of around 0.8 g/kg/day among those individuals 
with CKD stages 3–5 who are highly motivated to follow 
such a diet  [3] . Other recommendations suggest a lower 
range of protein restriction to 0.6–0.8 g/kg/day, provided 
that signs of malnutrition are not present  [4] .
 Whether patients with CKD should be prescribed a 
restricted dietary protein has been a matter of much de-
bate. The largest randomized controlled trial (RCT) per-
formed to date, the Modification of Diet in Renal Dis-
eases (MDRD) study, included about 600 individuals 
with moderate CKD and showed that a low- versus usual-
protein diet (0.58 vs. 1.3 g/kg/day) did not result in slow-
er decline of kidney function  [5] . Other smaller RCTs 
showed that protein restriction to approximately 0.6–0.8 
g/kg/day was associated with a modest and not significant 
benefit on CKD progression  [6, 7] . In clinical trials in-
cluding insulin-dependent diabetic nephropathy pa-
tients, low-protein diets (LPDs) resulted in slower decline 
of glomerular filtration rate (GFR)  [8, 9] . A meta-analysis 
that involved about 1,500 patients suggested a 39% lower 
risk of kidney failure or death in patients randomly as-
signed to LPD  [10] . A more recent systematic review me-
ta-analyzed studies specifically addressing patients with 
CKD stages 1–3 and found no reduction in mortality or 
ESRD after an LPD  [11] . Differences in the inclusion cri-
teria, degree of proteinuria or type of protein provided 
may have affected the results of the studies mentioned 
above. Because present data are not firmly conclusive, di-
etary protein restriction cannot be recommended as a 
 routine kidney protective strategy for patients with CKD. 
However, the reported safety of LPDs and their beneficial 
effects on uremic symptoms are obvious and justify its 
prescription for most CKD patients.
 One concern regarding LPDs is that they might com-
promise nutritional status in the long term, especially in 
those individuals with concurrent conditions that would 
require higher amounts of proteins such as infections, 
metabolic acidosis or other procatabolic states. Despite 
this common concern, RCTs show that a LPD does not 
seem to result in malnutrition  [5–7] , though patients in 
studies are subjected to more stringent dietary counseling 
and control than is common in clinical practice. Monitor-
ing of nutritional status must therefore be implemented 
if protein-restricted diets are prescribed. Adequate calor-
ic intake must be ensured and at least 60% of the ingested 
protein must be of high biologic value or contain a high 
percentage of essential amino acids to ensure net neutral 
nitrogen balance. Because dietary protein is a source of 
metabolic acids that stimulate skeletal muscle protein 
breakdown, LPDs may be associated with less metabolic 
acidosis. If the patients appear to be at risk of malnutri-
tion, the LPD can be supplemented with essential amino 
acids and/or keto acids. The use hypercaloric renal-spe-
cific supplements in the context of an LPD has been as-
sociated with protein intake closer to the target values, 
better nutritional measures and better adherence to ther-
apy than an LPD alone  [12] . Likewise, ketoanalogues of 
essential amino acids (keto acids) can also be used based 
on their capacity to neutralize the excessive nitrogen res-
idues through transamination and limit the production 
of urea, thus breaking the vicious cycle of the disease 
while at the same time allowing the preservation of nutri-
tional status  [13] . It has been postulated that besides the 
amount of dietary protein, the source of protein could 
also be important and that vegetable protein or egg whites 
are preferable  [14, 15] . Vegetable sources of protein might 
have additional benefits that motivate its recommenda-
tion in CKD patients such as lower organic phosphorus 
absorption and, consequently, lower serum phosphate 
levels and decreased fibroblast growth factor-23  [16] . 
Vegetarian diets may also decrease the production of ure-
mic toxins such as p-cresyl sulfate and indoxyl sulfate 
 [17] , which have been implicated in CKD progression 
 [18] . Finally, a diet high in vegetables might lead to lower 
endogenous production of acid  [19] .
 Adherence to a protein diet with 0.6 g/kg/day of pro-
teins is often difficult. Nutritional education programs 
and dietitians’ advice are effective in increasing patient 
adherence to low-protein intake recommendations  [20] . 
The support of the patient by family members and who-
ever prepares the food is also critical. To maintain this 
change over time, the LPD prescribed has to be pleasant, 
varied and not too restrictive. A recent Italian study pro-
posed a simplified approach to an LPD feasible for the 
patients and for implementation in the clinic  [21] . The 
authors proposed to their patients a simplified vegetarian 
LPD supplemented with ketoanalogues. The simplified 
diet was based on a concept of forbidden and allowed 
foods [forbidden: fish, meat, milk, eggs and derivatives 
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thing else is allowed]. The diet was essentially vegan, with 
an average protein intake of 0.6 g/kg/day and an average 
energy intake of 30–35 kcal/kg/day, supplemented with 
ketoanalogues. To improve compliance, 1–3 free-choice 
meals per week were allowed and the foods are not 
weighed. Adherence and feasibility were good and the 
findings were able suggest an easier method to achieve 
dietary protein restriction.
 Salt Restriction 
 High dietary sodium is an important determinant of 
blood pressure, predisposing patients with established 
CKD to salt-sensitive hypertension and fluid retention. 
Higher dietary sodium intake has been associated with 
GFR decline in the community  [22] . Dietary salt restric-
tive approaches like the DASH diet  [23] are effective in 
reducing blood pressure. However, there is presently no 
evidence that a reduction of dietary sodium will retard 
CKD progression. In individuals with CKD, sodium re-
striction has been shown to enhance the effects of various 
antiproteinuric drugs such as angiotensin receptor block-
ers  [24] . More interestingly, an interventional study  [25] 
assigned 176 patients with nondialyzed hypertensive 
CKD to a low-sodium diet (2,300 mg/day) over 7 days, 
and reported (vs. a control group) that sodium restriction 
resulted in a greater reduction in blood pressure as well 
as a reduction in urine protein excretion. Despite these 
encouraging findings, intensive reduction in dietary so-
dium may be difficult to achieve due to poor adherence. 
The main reasons for poor adherence are (1) worse taste/
palatability of low-sodium foods, (2) availability and cost 
of low-sodium foods, (3) interference with socialization, 
and (4) lack of perceived benefit and inability to identify 
low sodium foods. The advice and follow-up of nutrition-
ists is probably needed to improve patient motivation and 
compliance. Current guidelines recommend an upper 
limit of 2–3 g of salt per day in nondialyzed CKD patients 
for blood pressure and volume control as well as for im-
proving the efficacy of antiproteinuric medication  [26, 
27] .
 Other Beneficial Dietary Approaches 
 Recent studies suggest additional potential benefits of 
healthy eating on CKD progression. In the community, 
individuals consuming too much saturated fat are more 
likely to progress to CKD  [22] . In those with manifest 
CKD, a meta-analysis of RCTs addressing the impact of 
n–3 polyunsaturated fatty acids (present in fish oil) on 
proteinuria and renal function reported a greater reduc-
tion in urine protein excretion with this dietary interven-
tion  [28] . When recommending fish intake to CKD pa-
tients, however, knowledge of the phosphate-to-protein 
ratio in different fish species is recommended. Growing 
evidence suggests potential benefit of dietary fat modifi-
cation strategies in CKD patients, including increasing 
the amount of linoleic acid (n–6 PUFA) from vegetable 
oils and thus reducing the amount of saturated fat ingest-
ed  [29, 30] . 
 A high consumption of sugary drinks/sodas has been 
associated with the incidence of albuminuria, CKD and 
faster GFR decline in the community  [31, 32] . However, 
there is no evidence from interventional studies to sup-
port these observational data. An RCT in people with 
CKD stages 2–3 reported that a low-fructose diet was able 
to significantly reduce a number of inflammatory bio-
markers and blood pressure versus a control group con-
suming their habitual fructose intake  [33] . A recent study 
found that lower fiber intake was associated with elevated 
serum CRP levels and increased mortality in people with 
CKD  [34] . Hypovitaminosis D has also been associated 
with ESRD initiation in people with CKD stages 4–5, an 
association that is explained in part by fibroblast growth 
factor-23-dependent pathways  [35] . In a series of RCTs, 
a higher intake of fruits and vegetables was compared to 
the efficacy of oral bicarbonate in people with CKD stag-
es 1–4. The rationale was that high-alkali fruit intake 
would reduce the dietary acid load and be able to control 
acidosis and subsequent kidney injury. In CKD stage 2, 
both treatments attenuated kidney injury to a similar ex-
tent  [36] . In CKD stages 3–4, metabolic acidosis was sig-
nificantly reduced by both treatments (although, as ex-
pected, more in the bicarbonate group)  [37] . With in-
creased but controlled fruit/vegetable intake, hyperkalemia 
was not induced  [37] .
 All these associations between healthy nutrients and 
CKD may be the result of healthy eating in general. Con-
sistent with this notion, increased urine albumin excre-
tion and higher odds of rapid decline in estimated GFR 
rate have been reported among individuals with consis-
tent Western dietary patterns  [2] . In a population-based 
study, greater adherence to a Mediterranean diet was as-
sociated with lower odds of current CKD and was a pre-
dictor of mortality in those with manifest CKD  [38] . Fi-
nally, a healthy diet is often accompanied by other healthy 
habits that may impact on kidney function. A recent 
study showed that adherence to a healthy lifestyle (as-
sessed on the basis of smoking habits, BMI, physical activ-
ity and dietary quality) was associated with lower all-
cause mortality risk in people with CKD stage 3 or more 
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 Phosphate Control and CKD Progression 
 Because organic phosphorus is bound to protein, the 
amount of protein eaten will predictably determine phos-
phorus intake. The intestinal absorption of organic phos-
phorus is lower if coming from animal sources (absorbed 
by 40–60%) than from vegetable sources (absorbed by 10–
30%). However, inorganic phosphorus presently added to 
processed foods is almost entirely absorbed in the intes-
tine. Because the amounts of inorganic phosphorus are 
often not reported in processed food labels, estimation of 
the real phosphorus intake of CKD patients is challenging 
and likely exceeds recommendations. Since there are 
physiological adaptations to counteract excessive phos-
phorus retention, hyperphosphatemia typically occurs 
only when patients reach CKD stages 4–5  [40] . This means 
that dietary phosphorus restriction is generally not neces-
sary in earlier stages. In CKD stage 4–5, elevated phos-
phate levels were reported to be direct predictors of mor-
tality  [41] . Current recommendations for phosphorus in-
take in CKD stages 3–5 are to reduce intake to 800–1,000 
mg/day, in conjunction with use of phosphate binders if 
considered necessary  [4] . Although noncontrolled evi-
dence is not unanimous in this regard, a recent RCT sug-
gested that a low-phosphorus diet is able to decrease se-
rum phosphorus and fibroblast growth factor-23 levels 
 [42] . Another recent RCT showed that the combined pre-
scription of this diet and phosphate binders proved to be 
more effective than each of these approaches alone  [43] . 
Whenever serum phosphorus is high, regardless of the 
CKD stage, it seems reasonable to restrict phosphorus in-
take in addition or not to phosphorus binder prescription.
 By reducing the amount of dietary phosphorus ab-
sorbed from the gut, phosphate binders help to control 
serum phosphorus levels and are used by 70–90% of pa-
tients receiving hemodialysis in Europe  [44] . Clinical tri-
als have confirmed that phosphate binders effectively re-
duce serum phosphorus in healthy participants, patients 
not yet undergoing dialysis and patients receiving long-
term dialysis for ESRD  [45, 46] . Thus, it has been pro-
posed that people with CKD may receive phosphate bind-
ers before dietary restrictions are advised. This could help 
to control serum phosphorus while maintaining high-
protein intake and good nutrition, thus avoiding the po-
tential for protein-energy wasting (PEW) and increased 
mortality associated with protein restriction. In support 
of this, the Dialysis Outcomes and Practice Patterns Study 
(DOPPS) showed that phosphate binder use was associ-
ated with improved survival and better nutritional status 
 [47] , perhaps due to a more liberal diet as allowed by 
phosphate binder use. Prospective interventional studies 
are needed to confirm these observational data.
 Studies have shown that the use of sevelamer- or lan-
thanum-based phosphate binders can greatly reduce the 
occurrence of calcification in laboratory models of chron-
ic renal failure. For example, studies of rat vascular smooth 
muscle cells illustrate that the presence of phosphorus in-
creases the incidence of calcification, and that lanthanum 
can attenuate this increase  [48] . Treatment of rats with 
chronic renal failure with 3% sevelamer or with 3% lantha-
num carbonate reduced the calcification of aortic root le-
sions to a similar extent  [48] . Sevelamer or lanthanum car-
bonate treatment has been shown to attenuate the devel-
opment of coronary and aortic calcifications in patients on 
maintenance hemodialysis to a greater extent than treat-
ment with calcium-based phosphate binders  [49] . Two re-
cent studies have shown a similar effect with lanthanum 
carbonate  [50, 51] . However, these potential benefits have 
not been associated with improved survival in large RCTs.
 Phosphorus overload may be detrimental to the cardio-
vascular prognosis in CKD. Nevertheless, no clinical trial 
has yet demonstrated that reducing phosphorus intake im-
proves survival in nondialyzed CKD patients or reduces 
CKD progression. The use of phosphate binders in CKD is 
based on observational rather than clinical trial data. The 
few studies available suggest a limited effect of phosphate 
binders, at least when used in ‘normophosphatemic’ pa-
tients and not in combination with diet  [52] . Furthermore, 
considering the limitations of available studies, more clin-
ical trials and follow-up analyses should investigate the im-
pact of phosphorus metabolism management (nutritional 
interventions and phosphate binder use) on outcomes at 
different serum phosphate levels and renal function.
 Because oral calcium carbonate affects calcium but not 
phosphorus balance in CKD stages 3–4  [53] , and adminis-
tration of calcium-containing phosphate binders in hemo-
dialysis patients is associated with increased vascular calci-
fication  [54] , concern has been raised regarding the safety 
of excess calcium intake in nondialyzed individuals with 
CKD. In a calcium balance study, normal individuals and 
patients with CKD stages 3–4 were in slightly negative to 
neutral calcium balance on an 800-mg/day calcium diet 
 [55] . Normal individuals were in modest positive calcium 
balance on a 2,000-mg/day diet, whereas CKD patients on 
the same diet were in marked positive calcium balance. Fur-
thermore, increased calcium intake significantly decreased 
1,25-dihydroxyvitamin D and PTH levels, but it did not 
alter the serum calcium concentration. On the basis of this 
study, a diet of 2,000 mg/day of calcium in CKD patients 
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calcium deposited in tissues leading to calcification. There-
fore, it seems reasonable to restrict total calcium intake to 
the currently recommended dose of 1,500 mg/day  [56] .
 Malnutrition in Patients with Nondialyzed CKD 
 Complications involving protein-energy status are rel-
atively common in ESRD stages and are associated with 
poor outcomes and disability. These complications have 
been collectively termed as PEW. The term PEW was de-
veloped in recognition that not all causes of wasting are 
due to inadequate nutrient intake. PEW is defined as ab-
normally low levels or excessive losses of body protein 
mass and energy reserves. Causes of PEW thus include 
inadequate nutrient intake, but also increased catabolism 
as induced by systemic inflammation, oxidative stress, 
imbalance in anabolism/catabolism, metabolic acidosis, 
abnormal glucose and insulin homeostasis, and vitamin 
D deficiency  [57, 58] . Recently, the role of male hypogo-
nadism (i.e. testosterone deficiency) in nondialyzed CKD 
patients has attracted renewed attention  [59] not only 
owing to its association with reduced muscle mass and 
strength  [60] , but also endothelial dysfunction and risk of 
cardiovascular events prior to dialysis initiation  [61] . 
Many of these conditions start to become especially ap-
parent in people with CKD when reaching stages 4 and 5. 
A decline in protein and energy intake is often followed 
by a worsening in nutritional status. An important aspect 
to consider in nutritional intake is the content of other 
nutrients in ingested foods. The dietary restrictions dis-
cussed above are necessary in CKD to control hyperkale-
mia, hyperphosphatemia, and calcium or sodium bal-
ance. However, if these restrictions are not accompanied 
by counseling on alternative food choices, they may result 
in nutritional deficiencies and appearance of malnutri-
tion. Relatively few studies have addressed the prevalence 
of malnutrition in nondialyzed CKD patients. Studies de-
fining malnutrition on the basis of hypoalbuminemia re-
port a prevalence of 20–45%  [62, 63] . Studies defining 
malnutrition on the basis of diagnostic tools like subjec-
tive global assessment report a prevalence of 18–20%  [64–
66] . Thus, it is reasonable to state that likely 1 out of 5 
people with CKD stages 4–5 will develop PEW prior to 
initiation of dialysis. The topic of screening and diagnosis 
of PEW in nondialyzed CKD is not covered in this review, 
but has been discussed elsewhere  [4, 67] . An opinion-
based algorithm for clinical assessment and management 
of malnutrition in nondialyzed CKD has recently been 
proposed  [68] .
 A critical aspect of malnutrition management in pre-
dialysis stages is the amount of energy ingested. Neutral 
or positive nitrogen balance requires adequate energy in-
take, and a low-energy intake may directly cause PEW. It 
is recommended that the daily energy intake in nondia-
lyzed CKD patients be approximately 35 kcal/kg/day in 
those aged <60 and 30 kcal/kg/day in those aged  ≥ 60 
years  [56] . These recommendations for energy intake 
may be modified when examination of an individual’s 
daily energy expenditure indicates different needs. When 
signs of malnutrition are present, the use of nutritional 
supplements may be indicated. However, the use of tra-
ditional supplements (protein-rich) may be counterintu-
itive if we advocate an LPD to avoid kidney damage. Hy-
percaloric supplements providing essential amino acids 
but with low-protein content could theoretically have 
some advantages versus traditional supplements, but are 
more expensive. Unfortunately, no interventional trials 
of nutritional support in malnourished patients with 
nondialyzed CKD have yet been published.
 Conclusion 
 Nutrient intake is likely to influence the risk for initia-
tion and progression of CKD as well as some of its associ-
ated complications. The evidence linking nutrition with 
occurrence and prognosis of CKD is unfortunately vari-
able and many nutrients have not been thoroughly inves-
tigated. Some topics like salt control and protein restric-
tion have more solid evidence to support their use in clin-
ical practice. However, in the context of present dietary 
trends, it may not be easy for patients to comply with such 
restrictions. To date, very little evidence exists on how to 
manage malnutrition in nondialyzed CKD. Education on 
nutritional approaches and adaptations in the context of 
CKD must be a part of patient management at both early 
and advanced stages. Such programs benefit from the ex-
pertise and dedication of nutritionists and dietitians, con-
tributing positively to patient motivation and adherence.
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